

CSE Symbol: IME
OTC PINK Symbol: IMEXF

NR-2016-IME-07

Imagin Medical Begins Trading on OTC

Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care for urologists in detecting bladder cancer through endoscopes.

Vancouver, B.C. and Boston, MA, April 28, 2016 – Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (the “Company”) announced that it has started trading on the OTC Pink Sheets under the symbol “IMEXF”. U.S. investors can now find quotes for the company on www.otcmarkets.com.

The Company’s common shares have been approved for DTC (Depository Trust Company) eligibility that allows Imagin Medical’s securities to be deposited electronically through DTC, the largest securities depository in the world, with over \$35 trillion worth of securities on deposit.

“Becoming DTC eligible will facilitate electronic settlement of transfers of our common shares in the United States,” said Jim Hutchens, Imagin Medical’s President & CEO. “It provides our shareholders with various benefits, including reducing the time for stock deposits and withdrawals to be transferred from brokerage accounts, and eliminating the inherent risks associated with the loss and replacement of physical stock certificates. In addition, we have seen that companies that are approved for DTC electronic transfers often experience higher trading volumes in their stock given the additional accessibility and availability of shares for trading. It makes sense to offer a public market for our prospective shareholders in the U.S., as we are developing the technology at the University of Rochester, Laboratory of Laser Energetics and will be targeting manufacturing and eventual commercial efforts in the United States.”

About Imagin Medical

Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced,

ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaqinmedical.com.

ON BEHALF OF THE BOARD:

Jim Hutchens,

President & CEO

For further information, contact:

Bill Galine, Investor Relations

Telephone: (775) 737-3292

Email: billgaline@gmail.com

CAUTIONARY DISCLAIMER STATEMENT: *The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.*

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.